

ASX ANNOUNCEMENT

R&D TAX CREDIT RECEIVED

Sydney, 13 June 2013: Benitec Biopharma Limited (ASX: BLT) today received a \$434,000 cash refund under the Federal Government's R&D Tax Incentives Scheme.

The tax refund relates to the costs of research and development conducted by the company which qualify for the scheme's 45% refund on eligible R&D expenditure.

The funds will be used to advance Benitec's product development programs, in particular its hepatitis C therapeutic, TT-034.

For more information please contact: Dr Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About TT-034 TT-034 is a potentially transformative therapeutic that is intended to provide a "one-shot-cure" for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance (a major problem for most hepatitis C drugs) by simultaneously silencing three separate highly conserved regions on the virus genome. Studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.